Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression

LSD microdosing reduces depression scores without major side effects, clinical trial finds

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder was feasible and well-tolerated, with Montgomery-Åsberg Depression Rating Scale (MADRS) scores reduced by 59.5% at the end of treatment and sustained to six months.

Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression

The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia. The post Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression appeared first on MedCity News.

A “Surprise” Miss: NBI-1070770 for Major Depressive Disorder Fails in Phase 2 Study

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

Neurocrine reports Phase 2 fail for depression drug it licensed from Takeda

Neurocrine Biosciences said that a candidate for major depressive disorder that it got from Takeda did not succeed in a mid-stage trial. The oral drug, codenamed NBI-1070770, did not meet the primary endpoint. This used ...

Neurocrine’s depression treatment misses main goal in Phase II study

Neurocrine Biosciences has reported that its Phase II trial assessing NBI-1070770 in adults with major depressive disorder failed to meet its primary goal when compared to a placebo.The post Neurocrine’s depression treatment misses main goal in Phase II study appeared first on Clinical Trials Arena.